Targeted antibody treatments offer hope for MPN patients with a CALR mutation
Researchers presented Phase 1 results for Incyte’s INCA33989 mutant-CALR antibody
at the European Hematology Association Congress in June, with trial participants in
both ET and MF showing encouraging early responses. Australia’s A/Professor David
Ross from South Australia has prepared this expert review of the findings for patients,
including upcoming clinical trials targeting the CALR mutation, offering clear insights
into what may be an important step forward in the treatment of CALR-positive ET and
MF.
